The Federal Trade Commission (FTC) is reportedly preparing to file a lawsuit against several prescription drug middlemen, alleging that their practices have contributed to inflated medication prices. This move is seen as part of a broader effort to address rising healthcare costs and protect consumers from price gouging.
According to sources familiar with the matter, the FTC’s investigation has focused on the role of pharmacy benefit managers (PBMs) in the pharmaceutical supply chain. PBMs act as intermediaries between drug manufacturers, pharmacies, and health insurers, negotiating drug prices and determining the formularies—or lists of covered medications—for insurance plans. Critics argue that PBMs often engage in opaque and anti-competitive practices that drive up drug costs for consumers and healthcare providers.
The lawsuit, which is expected to be filed in the coming weeks, will likely accuse PBMs of leveraging their market power to secure higher rebates from drug manufacturers while failing to pass on the savings to consumers. Instead, these rebates are purportedly used to boost the PBMs’ profits, leaving patients to bear the brunt of skyrocketing drug prices.
“The FTC’s action signals a significant crackdown on practices that have long been suspected of contributing to the high cost of prescription drugs in the United States,” said Robert Weissman, president of the consumer advocacy group Public Citizen. “By targeting PBMs, the FTC is aiming at a crucial node in the drug pricing ecosystem, which has remained largely unregulated and opaque.”
The lawsuit comes amid growing bipartisan pressure on regulators and lawmakers to address the issue of drug pricing. High medication costs have been a top concern for American consumers, with many reporting that they have had to skip doses, split pills, or forgo medications altogether due to affordability issues.
In response to the impending lawsuit, industry groups representing PBMs have argued that their members play a vital role in controlling drug costs and improving patient outcomes. They contend that PBMs negotiate discounts and rebates that ultimately benefit consumers by reducing overall drug spending.
“We are disappointed that the FTC is pursuing this misguided action,” said a spokesperson for the Pharmaceutical Care Management Association (PCMA), the trade group representing PBMs. “Our members work tirelessly to lower prescription drug costs and increase access to life-saving medications. We believe this lawsuit will harm consumers by undermining the very mechanisms that help control drug prices.”
However, healthcare advocates and some lawmakers have welcomed the FTC’s move, arguing that increased scrutiny of PBMs is long overdue. They point to instances where PBMs have been accused of engaging in practices such as spread pricing—where the PBM charges a health plan more for a drug than it reimburses the pharmacy, pocketing the difference—and formulary manipulation, which prioritizes higher-rebate drugs over more affordable or clinically appropriate alternatives.
“The American people deserve transparency and fairness in drug pricing,” said Senator Elizabeth Warren (D-MA), a vocal critic of the pharmaceutical industry. “For too long, PBMs have operated in the shadows, enriching themselves at the expense of patients. The FTC’s lawsuit is a crucial step towards holding these middlemen accountable and ensuring that patients can afford the medications they need.”
As the legal battle unfolds, the FTC’s action is expected to shine a spotlight on the complex and often contentious world of drug pricing, potentially paving the way for broader regulatory reforms aimed at curbing the influence of PBMs and making prescription medications more affordable for all Americans.
